Topical cannabinoid gel on dry sensitive skin: observational study

Introduction and clinical context

The study Topical cannabinoid gel on dry sensitive skin: observational study (PubMed · 2020) is part of the scientific research on the use of cannabinoids in dermatology.

In dermatology, cannabinoids are studied for their anti-inflammatory properties and for the role of the endocannabinoid system in the skin. The research covers conditions such as dermatitis, pruritus (itching), acne and psoriasis, generally with topical formulations. Most of the evidence comes from observational studies and scoping reviews; controlled clinical trials are still needed to confirm efficacy and safety.

Understanding what science shows about the use of cannabinoids in dermatology helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Observational study: improvement in itching and dermatitis with a topical cannabinoid gel. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

The skin has a functional endocannabinoid system, which regulates inflammation, itching and barrier function — the basis for the topical use of cannabinoids in dermatology, with CBD and other compounds acting through an anti-inflammatory and itch-modulating effect. Since these are generally topical formulations, systemic exposure is low and safety is usually favorable, with local irritation as the main risk. Even so, the evidence is mostly observational, and the indication should consider the skin type and the dermatological condition, under professional guidance.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2020). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis work for the skin?

Topical formulations are studied for inflammation and itching; the evidence is still mostly observational.

Does the skin have an endocannabinoid system?

Yes, and it takes part in regulating skin inflammation, which motivates the research.